


Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995 (National Stage of PCT/NZ2003/000186)
I.A. Filing Date: August 21, 2003

In the Claims:

A listing of the claims, with Claims 2-22, 24 and 25 as currently amended and Claim 28 as cancelled, is presented below.

1. (Original) A compound of the formula (I):



wherein:

V is selected from CH₂ and NH, and W is selected from NR¹ and NR²; or V is selected from NR¹ and NR², and W is selected from CH₂ and NH;


X is selected from CH₂ and CHOH in the R or S-configuration;

Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH, NR¹ and NR² then Y is hydrogen;


Z is selected from hydrogen, halogen, hydroxy, SQ, OQ and Q, where Q is an optionally substituted alkyl, aralkyl or aryl group;

R¹ is a radical of the formula (II)

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995 (National Stage of PCT/NZ2003/000186)
I.A. Filing Date: August 21, 2003



R² is a radical of the formula (III)



A is selected from N, CH and CR, where R is selected from halogen, optionally substituted alkyl, aralkyl or aryl, OH, NH₂, NHR³, NR³R⁴ and SR⁵, where R³, R⁴ and R⁵ are each optionally substituted alkyl, aralkyl or aryl groups;

B is selected from OH, NH₂, NHR⁶, SH, hydrogen and halogen, where R⁶ is an optionally substituted alkyl, aralkyl or aryl group;

D is selected from OH, NH₂, NHR⁷, hydrogen, halogen and SCH₃, where R⁷ is an optionally substituted alkyl, aralkyl or aryl group;

E is selected from N and CH;

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995 (National Stage of PCT/NZ2003/000186)
I.A. Filing Date: August 21, 2003

G is selected from CH₂ and NH, or G is absent, provided that where W is NR¹ or NR² and G is NH then V is CH₂, and provided that where V is NR¹ or NR² and G is NH then W is CH₂,

or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.

2. (Currently Amended) A compound as claimed in claim 1, where Z is selected from hydrogen, halogen, hydroxy, SQ and OQ.
3. (Currently Amended) A compound as claimed in claim 1, ~~or claim 2~~ where V is CH₂.
4. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 3~~ claim 1, where X is CH₂.
5. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 4~~ claim 1, where G is CH₂.
6. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 5~~ claim 1, where Z is OH.
7. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 5~~ claim 1, where Z is SQ.
8. (Currently Amended) A compound as claimed in ~~any one of claims 1, 3, 4 or 5~~ claim 1, where Z is Q.
9. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 8~~ claim 1, where W is NR¹.

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995 (National Stage of PCT/NZ2003/000186)
I.A. Filing Date: August 21, 2003

10. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 8~~ claim 1, where W is NR².

11. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 8~~ claim 1, where W is selected from NH, NR¹ or NR² and X is CH₂.

12. (Currently Amended) A compound as claimed in ~~any one of claims 1, 2, 3, 4, 5, 6 or 9~~ claim 1, where V, X and G are all CH₂, Z is OH and W is NR¹.

13. (Currently Amended) A compound as claimed in ~~any one of claims 1, 2, 3, 4, 5, 7 or 9~~ claim 1, where V, X and G are all CH₂, Z is SQ and W is NR¹.

14. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 13~~ claim 1, where Y is hydrogen.

15. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 13~~ claim 1, where Y is hydroxy.

16. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 15~~ claim 1, where B is hydroxy.

17. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 15~~ claim 1, where B is NH₂.

18. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 17~~ claim 1, where A is CH.

19. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 17~~ claim 1, where A is N.

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995 (National Stage of PCT/NZ2003/000186)
I.A. Filing Date: August 21, 2003

20. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 19~~ claim 1, where D is H.

21. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 19~~ claim 1, where D is NH₂.

22. (Currently Amended) A compound as claimed in ~~any one of claims 1 to 21~~ claim 1, where E is N.

23. (Original) A compound as claimed in claim 1, which is:

(3R,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4R)-1-[(9-Deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4R)-1-[(8-aza-9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)
pyrrolidine;
(3R,4R)-1-[(8-aza-9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(2-phenylethyl)pyrrolidine;
(3S,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3,4-dihydroxy-4-methylthiomethyl
pyrrolidine;
(3R,4S)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)
pyrrolidine;
N-(9-Deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol;
N-(9-deazahypoxanthin-9-yl)methyl-1,4-dideoxy-1,4-imino-D-ribitol;
(3R,4R)-3-hydroxy-4-hydroxymethyl-1-(hypoxanthin-9-yl)pyrrolidine;
(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine;
(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)pyrrolidine;
(3R,4S)-1-[(8-aza-9-deezaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)
pyrrolidine;
(3R,4R)-1-[(9-deazaguanin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(4-chlorophenylthiomethyl)
pyrrolidine;

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995 (National Stage of PCT/NZ2003/000186)
I.A. Filing Date: August 21, 2003

(3R,4R)-1-[(6-chloro-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4R)-1-[(6-azido-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine; or
(3R,4R)-1-[(9-deazaadenin-9-yl)methyl]-3-acetoxy-4-(acetoxymethyl)pyrrolidine;
or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.

24. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as claimed in ~~any one of claims 1 to 23~~ claim 1.

25. (Currently Amended) A method of treating a disease or condition in which it is desirable to inhibit purine phosphoribosyltransferase, purine nucleoside phosphorylase, 5'-methylthio adenosine phosphorylase, 5'-methylthioadenosine nucleosidase and/or nucleoside hydrolase comprising administering a pharmaceutically effective amount of a compound as claimed in ~~any one of claims 1 to 23~~ claim 1 to a patient requiring treatment.

26. (Original) The method of claim 25, where the disease or condition is cancer, bacterial infection, protozoal infection or a T-cell mediated disease.

27. (Original) The method of claim 26, where the T-cell mediated disease is psoriasis, arthritis or transplant rejection.

28. (Cancelled) The use of a compound as claimed in any one of claims 1 to 23 in the manufacture of a medicament for treating a disease or condition in which it is desirable to inhibit purine phosphoribosyltransferase, purine nucleoside phosphorylase, 5'-methylthioadenosine phosphorylase, 5'-methylthioadenosine nucleosidase and/or nucleoside hydrolase.